Advertisement
Advertisement
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
25.38
USDSponsored
-1.08
-4.08%
Sep 18, 15:59 UTC -4
Closed
After-Market
25.50
+0.12
+0.48%
ARQT Earnings Reports
Positive Surprise Ratio
ARQT beat 22 of 27 last estimates.
81%
Next Report
Date of Next Report
Oct 26, 2026
Estimate for Q3 26 (Revenue/ EPS)
$143.84M
/$0.16
Implied change from Q2 26 (Revenue/ EPS)
+10.76%
/+45.45%
Implied change from Q3 25 (Revenue/ EPS)
+44.97%
/+166.67%
Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Aug 05, 2026, ARQT reported earnings of 0.11 USD per share (EPS) for Q2 26, beating the estimate of 0.04 USD, resulting in a 150.57% surprise. Revenue reached 129.86 million, compared to an expected 121.23 million, with a 7.12% difference. The market reacted with a -2.47% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 6 analysts forecast an EPS of 0.16 USD, with revenue projected to reach 143.84 million USD, implying an increase of 45.45% EPS, and increase of 10.76% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
enGene Therapeutics Inc. Common Stock
Report Date
Sep 08, 2026 For Q3 26
Estimate
-$0.43
Actual
-$0.47
Surprise
-7.16%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Arcutis Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of $0.11, beating estimates by 150.57%, and revenue of $129.86M, 7.12% above expectations.
How did the market react to Arcutis Biotherapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -2.47%, changed from $27.10 before the earnings release to $26.43 the day after.
When is Arcutis Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 26, 2026.
What are the forecasts for Arcutis Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 6
analysts, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of $0.16 and revenue of $143.84M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.